HER2-Positive Breast Cancer Market By Treatment Type (Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy and Others), By Route of Administration (Parenteral, Oral and Others), By Application (Hospital, Biotechnology & Pharmaceuticals company, Specialty Clinics, Research & Academic Institution and Others), By Distribution Channel ( Hospital pharmacy, Retail pharmacy and Online pharmacy) and By Region - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI470421 | Publish Date: May 2024 | No. of Pages: 180

Global HER2 Positive Breast Cancer Market Companies

  • Eli Lilly and Company
  • Immunomedics
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd
  • Radius pharmaceuticals
  • Merck & Co. Inc
  • Bayer AG
  • GlaxoSmithKline plc
  • Syndax pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Novartis AG
  • Teva Pharmaceuticals Industries Ltd
  • Baxter
  • Mylan N.V.
  • Fresenius Kabi AG

Recent News:

  • In January 2024, AstraZeneca India Pharma Ltd., a science-led biopharmaceutical company officially launched Trastuzumab deruxtecan, therapy tailored for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer for those who have previously received an anti-HER2 regimen. Developed in collaboration with Daiichi Sankyo, Trastuzumab deruxtecan is a specifically engineered HER2-directed antibody drug conjugate (ADC).